Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 1.06% to $480.50 on Monday, underperforming the broader market as the S&P 500 and Dow Jones also declined. This marks the second consecutive day of losses for VRTX, which remains near its 52-week high. Trading volume was below the 50-day average. While competitors like AbbVie and Krystal Biotech also saw declines, Vertex's drop was more pronounced relative to some peers.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 1.06% to $480.50 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.19% to 7,443.28 and Dow Jones Industrial Average falling 0.59% to 51,839.26.
This was the stock's second consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 9.96% short of its 52-week high of $533.67, which the company achieved on July 7th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc. (ABBV) fell 0.44% to $253.38, Krystal Biotech Inc. (KRYS) fell 4.41% to $339.22, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.32% to $5.97.
Trading volume (1.1 M) remained 499,021 below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-20-26 1637ET